The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.

Publication date: Jul 09, 2019

Targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not are commonly used in patients with melanoma brain metastases, but studies that directly compare these strategies are lacking. The current meta-analysis aimed to better elucidate their activity and efficacy.

A systematic search of MEDLINE, Embase, and conference proceedings up to January 2019 was performed to identify trials investigating combination TT, monotargeted TT (mono TT), MI, CMI, and CRI in melanoma brain metastases. The outcomes considered were progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) as evaluated at both intracranial and extracranial sites. Random effects models were used to compare the different therapeutic strategies.

A total of 15 trials were included that provided 1132 patients for analyses. CMI demonstrated a statistically significant better OS compared with MI (P = .03, P = .05, and P = .03, respectively, at 6 months, 18 months, and 24 months) and combination TT (P = .04 and P = .03, respectively, at 18 months and 24 months). CMI demonstrated a statistically significant better PFS compared with combination TT (P

Rulli, E., Legramandi, L., Salvati, L., and Mandala, M. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. 23320. 2019 Cancer.

Concepts Keywords
Embase Clinical medicine
Immunotherapy Antineoplastic drugs
MEDLINE Health
Melanoma Cancer
Meta Analysis Melanoma
Mono Brain tumor
Radiotherapy RTT
Targeted Therapies Medicine
Immunotherapy
Radiotherapy
Brain metastasis
Progression-free survival
Targeted therapy

Semantics

Type Source Name
drug DRUGBANK Tropicamide
disease MESH metastases
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
gene UNIPROT IMPACT

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *